Fulvestrant 250 mg/5 mL
| Product Overview |
| Generic Name | Fulvestrant 250 mg/5 mL |
| Brand Name(s) | Faslodex, Perjeta |
| Form | Solution for intramuscular injection, vials containing 250 mg/5 mL |
| Strength | 250 mg per 5 mL (50 mg/mL) |
| Therapeutic Class | Estrogen receptor antagonist (selective) |
| ATC Code | L02BA03 |
| Manufacturing & Regulatory |
| Manufacturer | AstraZeneca (Faslodex); EVER Pharma (Fulvestrant) |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Not publicly disclosed |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export |
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store in cool, dry place (supplier); protect from light; refrigerate per label if recommended |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Upon Request, not publicly posted |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Indications & Usage: Fulvestrant 250 mg/5 mL IM injection is indicated for estrogen receptor–positive, locally advanced or metastatic breast cancer in postmenopausal women— either as monotherapy or combined with palbociclib in HR+/HER2– cases ([[SMPC]]
Request for Quote
